People at high risk for recurrent cardiac events following percutaneous coronary intervention (PCI), a procedure to open blocked arteries, ...

Christian T. Ruff, MD, MPH, of Brigham and Women's Faulkner Hospital, discusses new data comparing abelacimab with ...

A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million Americans over the age of 40, is ...

A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor's antiplatelet effects in patients undergoing urgent surgery or experiencing major ...

Patients who have a stent implanted to open a blocked coronary artery face dual risks of developing blood clots and of having ...

In the RIVAWAR trial, patients hospitalized for a heart attack who were treated with rivaroxaban for left ventricular ...

Three months of dual antiplatelet therapy after PCI may safely balance thrombosis and bleeding risk in both patients with low ...

A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor’s antiplatelet effects in patients ...

Late-breaking data showed almost all patients achieved normal blood clotting and vessel repair after bentracimab infusion.

In a groundbreaking initiative, former President Donald Trump is poised to unveil a $150 trillion national 'endowment”, a move that could redefine the economic landscape of the United States. This ...